Clomicalm

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

clomipramine hydrochloride

Available from:

Virbac S.A.

ATC code:

QN06AA04

INN (International Name):

Clomipramine

Therapeutic group:

Psi

Therapeutic area:

Psihoanaleptiki

Therapeutic indications:

As an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.

Product summary:

Revision: 18

Authorization status:

Pooblaščeni

Authorization date:

1998-04-01

Patient Information leaflet

                                15
B. NAVODILO ZA UPORABO
16
NAVODILO ZA UPORABO
CLOMICALM 5 MG TABLETE ZA PSE
CLOMICALM 20 MG TABLETE ZA PSE
CLOMICALM 80 MG TABLETE ZA PSE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom in proizvajalec odgovoren za
sproščanje serij:
VIRBAC
1ère avenue – 2065 m – LID
06516 Carros
Francija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Clomicalm 5 mg tablete za pse
Clomicalm 20 mg tablete za pse
Clomicalm 80 mg tablete za pse
klomipraminijev klorid
3.
NAVEDBA UČINKOVIN(E) IN DRUGIH SESTAVIN
5 mg klomipraminijevega klorida (kar ustreza 4,5 mg klomipramina).
20 mg klomipraminijevega klorida (kar ustreza 17,9 mg klomipramina).
80 mg klomipraminijevega klorida (kar ustreza 71,7 mg klomipramina).
5 mg tableta: rjavkasto-siva, ovalno podolgovata, deljiva. Na obeh
straneh je zareza.
20 mg tableta: rjavkasto-siva, ovalno podolgovata, deljiva. Na eni
strani je vtisnjena oznaka ‘C/G’, na
drugi strani oznaka ‘G/N’ in zareza na obeh straneh.
80 mg tableta: rjavkasto-siva, ovalno podolgovata, deljiva. Na eni
strani je vtisnjena oznaka ‘I/I’, na
drugi strani ni oznake in zareza je na obeh straneh.
4.
INDIKACIJA(E)
Kot pomoč pri zdravljenju specifičnih vedenjskih motenj pri psih, ki
se manifestirajo z destrukcijo in
nenadzorovanim izločanjem (defekacijo in uriniranjem), skupaj s
terapevtskimi tehnikami odprave
vedenjskih motenj.
5.
KONTRAINDIKACIJE
Ne uporabite v primerih preobčutljivosti na klomipramin in podobne
triciklične antidepresive.
Ne uporabite pri samcih, namenjenih za vzrejo.
6.
NEŽELENI UČINKI
17
Zelo redko lahko zdravilo Clomicalm povzroči bruhanje, spremembe
apetita, letargijo ali povišane
ravni jetrnih encimov; učinki so reverzibilni, ko se z zdravljenjem
preneha. Poročali so o jeterno-
žolčnih boleznih, predvsem, če so že prej obstajali pogoji zanje
in pri sočasni uporabi zdravil, ki se
presnavljajo preko jetrnega sistema. Bruhanje lahko zmanj
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Clomicalm 5 mg tablete za pse
Clomicalm 20 mg tablete za pse
Clomicalm 80 mg tablete za pse
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vsaka tableta zdravila Clomicalm vsebuje:
UČINKOVINA:
klomipraminijev klorid
5 mg (kar ustreza 4,5 mg klomipramina)
klomipraminijev klorid
20 mg (kar ustreza 17,9 mg klomipramina)
klomipraminijev klorid
80 mg (kar ustreza 71,7 mg klomipramina)
POMOŽNE SNOVI:
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Tablete.
5 mg tableta: rjavkasto-siva, ovalno podolgovata, deljiva. Na obeh
straneh je zareza.
20 mg tableta: rjavkasto-siva, ovalno podolgovata, deljiva. Na eni
strani je vtisnjena oznaka ‘C/G’, na
drugi strani oznaka ‘G/N’ in zareza na obeh straneh.
80 mg tableta: rjavkasto-siva, ovalno podolgovata, deljiva. Na eni
strani je vtisnjena oznaka ‘I/I’, na
drugi strani ni oznake in zareza je na obeh straneh.
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Pes.
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Kot pomoč pri zdravljenju specifičnih vedenjskih motenj pri psih, ki
se manifestirajo z destrukcijo in
nenadzorovanim izločanjem (defekacijo in uriniranjem), skupaj s
terapevtskimi tehnikami odprave
vedenjskih motenj.
4.3
KONTRAINDIKACIJE
Ne uporabite v primerih preobčutljivosti na klomipramin in podobne
triciklične antidepresive.
Ne uporabite pri samcih, namenjenih za vzrejo.
4.4
POSEBNA OPOZORILA ZA VSAKO CILJNO ŽIVALSKO VRSTO
Ni podatkov o varnosti in učinkovitosti pri uporabi tega zdravila pri
psih, lažjih od 1,25 kg in mlajših
od 6 mesecev.
4.5
POSEBNI PREVIDNOSTNI UKREPI
3
Posebni previdnostni ukrepi za uporabo pri živalih
Priporočljiva je previdna uporaba pri psih z motnjami v delovanju
kardiovaskularnega sistema ali
epilepsijo in samo po oceni razmerja korist-tveganje. Zaradi njegovih
potencialnih antiholinergičnih
lastnosti je potrebna previdna uporaba tudi pri psih, ki imajo
glavkom, zmanjšano gastrointestinal
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-10-2021
Public Assessment Report Public Assessment Report Bulgarian 01-07-2016
Patient Information leaflet Patient Information leaflet Spanish 25-10-2021
Public Assessment Report Public Assessment Report Spanish 01-07-2016
Patient Information leaflet Patient Information leaflet Czech 25-10-2021
Public Assessment Report Public Assessment Report Czech 01-07-2016
Patient Information leaflet Patient Information leaflet Danish 25-10-2021
Public Assessment Report Public Assessment Report Danish 01-07-2016
Patient Information leaflet Patient Information leaflet German 25-10-2021
Public Assessment Report Public Assessment Report German 01-07-2016
Patient Information leaflet Patient Information leaflet Estonian 25-10-2021
Public Assessment Report Public Assessment Report Estonian 01-07-2016
Patient Information leaflet Patient Information leaflet Greek 25-10-2021
Public Assessment Report Public Assessment Report Greek 01-07-2016
Patient Information leaflet Patient Information leaflet English 25-10-2021
Public Assessment Report Public Assessment Report English 01-07-2016
Patient Information leaflet Patient Information leaflet French 25-10-2021
Public Assessment Report Public Assessment Report French 01-07-2016
Patient Information leaflet Patient Information leaflet Italian 25-10-2021
Public Assessment Report Public Assessment Report Italian 01-07-2016
Patient Information leaflet Patient Information leaflet Latvian 25-10-2021
Public Assessment Report Public Assessment Report Latvian 01-07-2016
Patient Information leaflet Patient Information leaflet Lithuanian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-10-2021
Public Assessment Report Public Assessment Report Lithuanian 01-07-2016
Patient Information leaflet Patient Information leaflet Hungarian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 25-10-2021
Public Assessment Report Public Assessment Report Hungarian 01-07-2016
Patient Information leaflet Patient Information leaflet Maltese 25-10-2021
Public Assessment Report Public Assessment Report Maltese 01-07-2016
Patient Information leaflet Patient Information leaflet Dutch 25-10-2021
Public Assessment Report Public Assessment Report Dutch 01-07-2016
Patient Information leaflet Patient Information leaflet Polish 25-10-2021
Public Assessment Report Public Assessment Report Polish 01-07-2016
Patient Information leaflet Patient Information leaflet Portuguese 25-10-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 25-10-2021
Public Assessment Report Public Assessment Report Portuguese 01-07-2016
Patient Information leaflet Patient Information leaflet Romanian 25-10-2021
Public Assessment Report Public Assessment Report Romanian 01-07-2016
Patient Information leaflet Patient Information leaflet Slovak 25-10-2021
Public Assessment Report Public Assessment Report Slovak 01-07-2016
Patient Information leaflet Patient Information leaflet Finnish 25-10-2021
Public Assessment Report Public Assessment Report Finnish 01-07-2016
Patient Information leaflet Patient Information leaflet Swedish 25-10-2021
Public Assessment Report Public Assessment Report Swedish 01-07-2016
Patient Information leaflet Patient Information leaflet Norwegian 25-10-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 25-10-2021
Patient Information leaflet Patient Information leaflet Icelandic 25-10-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 25-10-2021
Patient Information leaflet Patient Information leaflet Croatian 25-10-2021
Public Assessment Report Public Assessment Report Croatian 01-07-2016

Search alerts related to this product

View documents history